{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Biomni 101"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Welcome to Biomni! Here is a simple tutorial on the basics of Biomni package. After you installed the environment, you can then simply try this to initialize the agent, which will automatically download the raw data lake files:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Checking and downloading missing data lake files...\n"
     ]
    }
   ],
   "source": [
    "import sys, os\n",
    "\n",
    "sys.path.insert(0, \"../\")  # This puts the local directory at the start of the path\n",
    "from biomni.agent import A1\n",
    "\n",
    "openai_api_key=os.getenv(\"OPENAI_API_KEY\")\n",
    "azure_endpoint=os.getenv(\"OPENAI_ENDPOINT\")\n",
    "\n",
    "agent = A1(path=\"/dfs/project/bioagentos/biomni_data_test\", llm=\"o3\", base_url=azure_endpoint, api_key=openai_api_key)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Then, you can simply start prompting the agent with the desired biomedical research task!"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "client=<openai.resources.chat.completions.completions.Completions object at 0x000001CF14C994D0> async_client=<openai.resources.chat.completions.completions.AsyncCompletions object at 0x000001CF160A1290> root_client=<openai.lib.azure.AzureOpenAI object at 0x000001CF14A87DD0> root_async_client=<openai.lib.azure.AsyncAzureOpenAI object at 0x000001CF14C99710> temperature=1.0 model_kwargs={} openai_api_key=SecretStr('**********') disabled_params={'parallel_tool_calls': None} azure_endpoint='https://esqai.openai.azure.com/' deployment_name='o3' openai_api_version='2024-12-01-preview' openai_api_type='azure'\n",
      "Using prompt-based retrieval with the agent's LLM\n",
      "================================\u001b[1m Human Message \u001b[0m=================================\n",
      "\n",
      "Find all necessary data to do a PBPK simulation with PK-Sim/MoBi of Sildenafil and give a detailed description on how to set up the simulation.\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "<solution>\n",
      "Below is a ready-to-use guide that contains  \n",
      "\n",
      "A.  All compound-specific data that you ordinarily have to collect before building a PBPK model of sildenafil in PK-Sim/MoBi (physicochemical, ADME, formulation and plasma-protein parameters, plus clinical study information for model qualification)  \n",
      "\n",
      "B.  A step-by-step protocol that shows exactly how to enter those data and run/verify the simulation in PK-Sim and (optionally) MoBi.  \n",
      "The data come from the FDA label, peer-reviewed literature and the Open Systems Pharmacology (OSP) knowledgebase; references are provided.  No proprietary information is required.\n",
      "\n",
      "────────────────────────────────────────────────────────\n",
      "A.  Sildenafil – compound data package for PBPK modeling\n",
      "────────────────────────────────────────────────────────\n",
      "1. Physicochemical properties  \n",
      "   • Molecular weight: 474.6 g·mol⁻¹  \n",
      "   • Compound type: monoprotic base (pKa = 8.7 for piperazine N, 6.1 for pyrazole N)  \n",
      "   • logP (octanol/water, neutral species, 25 °C): 2.6  \n",
      "   • Reference solubility at 25 °C, pH 7: 3.5 mg·L⁻¹ (in water)  \n",
      "   • BCS/BDDCS class: II (low solubility, high permeability)  \n",
      "   • Fraction unbound in plasma (fu): 0.036 (i.e. 96.4 % plasma-protein bound, mainly to albumin)  \n",
      "   • Blood-to-plasma ratio (B:P): 1.0  \n",
      "   • pKa,logP and solubility profiles versus pH are available in:  \n",
      "     – Hyland et al., 2001. Drug Metab Dispos 29: 272–278  \n",
      "     – FDA NDA 020895 clinical pharmacology review.\n",
      "\n",
      "2. Absorption parameters – immediate-release tablet  \n",
      "   • Product strength most commonly modeled: 50 mg film-coated tablet  \n",
      "   • In vitro dissolution: > 85 % in 0.1 N HCl within 30 min (sink conditions)  \n",
      "   • Effective human jejunal permeability (Peff,human): 1.7 × 10⁻⁴ cm·s⁻¹ (average of in-silico and Caco-2 back-calculation from high F ≈ 0.4)  \n",
      "   • GI degradation: negligible  \n",
      "   • Oral bioavailability (observed): 40 % (controls for first-pass & solubility limits)  \n",
      "\n",
      "3. Distribution parameters  \n",
      "   • Plasma-protein binding: as above (fu = 0.036) – albumin-binding class 2  \n",
      "   • Cellular binding: logP 2.6 and basic pKa ⇒ moderate lysosomal trapping; can keep PK-Sim default “moderate lipophilicity basic compound” setting.  \n",
      "   • Specific distribution coefficients (“Kp”) can be predicted by PK-Sim’s standard Rodgers & Rowland method; published whole-body Vss ≈ 1 L·kg⁻¹ (healthy male); calibrate by adjusting lipophilicity scalar if needed.  \n",
      "\n",
      "4. Metabolism parameters  \n",
      "   • Clearance mechanism: > 90 % hepatic oxidative metabolism, mainly CYP3A4 (≈ 80 %) and CYP2C9 (≈ 20 %).  \n",
      "   • Fraction metabolized (fm): 0.8 (CYP3A4), 0.2 (CYP2C9).  \n",
      "   • In vitro CLint (microsomes, fu,inc = 0.78): 7.2 µL·min⁻¹·mg protein⁻¹ (Yuan et al., 2002).  \n",
      "   • Scaled hepatic intrinsic clearance (Hepatic CLint,total): 38 L·h⁻¹ (after mg-protein scaling).  \n",
      "   • Renal clearance: 3 % of total (0.5 L·h⁻¹).  \n",
      "   • Enterocyte metabolism: include CYP3A4 abundance 19 pmol·mg⁻¹; same CLint scaling as liver.  \n",
      "\n",
      "5. Transporters  \n",
      "   • No evidence for clinically relevant efflux or uptake transport (BCRP, P-gp, OATPs tested negative). Default “no transporter” is acceptable.  \n",
      "\n",
      "6. Enzyme kinetic parameters (for DDI simulations, optional)  \n",
      "   – Km (CYP3A4): 3.6 µM; Vmax 1.8 pmol·min⁻¹·pmol CYP⁻¹  \n",
      "   – Km (CYP2C9): 13 µM; Vmax 0.45 pmol·min⁻¹·pmol CYP⁻¹  \n",
      "   (Back-calculated from CLint; see Hyland 2001).\n",
      "\n",
      "7. Clinical data for model verification  \n",
      "   (all studies fasted, healthy male, n ≥ 8)  \n",
      "   • 50 mg p.o., mean plasma profile 0–24 h (Bucks et al., Br J Clin Pharmacol 2004).  \n",
      "   • 25, 50, 100 mg p.o. dose-proportionality study (Nichols et al., Biopharm Drug Dispos 2002) – use Cmax/AUC.  \n",
      "   • 10 mg i.v. infusion over 30 min (Nichols 2002) – gives absolute F and Vss.  \n",
      "   • Food effect: 50 mg p.o. high-fat breakfast (Bucks 2004).  \n",
      "   • DDIs for qualification (optional): 50 mg with ketoconazole (200 mg b.i.d.) ↑ AUC ≈ 3.0; 50 mg with rifampicin ↓ AUC ≈ 0.6.\n",
      "\n",
      "────────────────────────────────────────────────────────\n",
      "B.  Step-by-step set-up in PK-Sim / MoBi\n",
      "────────────────────────────────────────────────────────\n",
      "(Software version used in this description: PK-Sim & MoBi 11.1; steps are identical for 10.x and 11.x.)\n",
      "\n",
      "1. Create a new project  \n",
      "   • Open PK-Sim → File > New Project → choose working directory.\n",
      "\n",
      "2. Define the compound  \n",
      "   a) Right-click “Building Blocks” → Compound → New.  \n",
      "   b) General tab  \n",
      "      – Name: Sildenafil  \n",
      "      – Molecular weight: 474.6 g · mol⁻¹  \n",
      "      – lipophilicity method: logP = 2.6 (shake-flask)  \n",
      "      – Fraction unbound plasma (fu): 0.036  \n",
      "      – B:P ratio: 1.0  \n",
      "   c) pKa tab – enter two basic pKa values 8.7 and 6.1.  \n",
      "   d) Solubility tab – type-in reference solubility 3.5 mg·L⁻¹ at pH 7 and 25 °C. Leave temperature dependence default (0 %/°C) unless you have full curve.  \n",
      "   e) Distribution tab – keep Rodgers & Rowland. Check “Use beta-scaling” if you need to fit Vss later.  \n",
      "   f) Enzymes & Transporters tab  \n",
      "      • Click “Add” → Enzyme → CYP3A4, location “Liver; Intracellular”; set CLint = 30.4 L·h⁻¹ (80 % of 38 L·h⁻¹).  \n",
      "      • Add second entry CYP2C9 CLint = 7.6 L·h⁻¹.  \n",
      "      • Add CYP3A4 in “Intestine, Intracellular” with CLint scaled by abundance ratio (liver/intestine ≈ 5) → 6 L·h⁻¹.  \n",
      "      • Renal clearance: go to “Eliminations” tab, check “Add renal clearance”, value 0.5 L·h⁻¹.  \n",
      "   g) Save compound.\n",
      "\n",
      "3. Create formulation (oral tablet)  \n",
      "   • Building Blocks → Formulation → New → Immediate-release oral.  \n",
      "   • Name: Sildenafil IR tablet 50 mg.  \n",
      "   • Enter unit dose strength 50 mg, fraction dissolved at dose strength 1 (100 %).  \n",
      "   • Dissolution profile: choose “Noyes-Whitney” or enter tabulated values (85 % at 30 min).  \n",
      "   • Save.\n",
      "\n",
      "4. Create the individual (healthy Caucasian male)  \n",
      "   • Building Blocks → Individual → New → Species = Human, Gender = Male, Age 30 yr, Weight 75 kg, Height 176 cm.  \n",
      "   • Keep default enzyme expression settings (verified vs. literature).  \n",
      "   • Save.\n",
      "\n",
      "5. Assemble the simulation  \n",
      "   a) Simulations → Create → “Oral administration” wizard.  \n",
      "   b) Select individual, compound, formulation.  \n",
      "   c) Dose 50 mg, single dose, empty stomach (select default gastric emptying).  \n",
      "   d) Finish to create simulation.\n",
      "\n",
      "6. Run and inspect base simulation  \n",
      "   • Press Run.  \n",
      "   • Plot plasma concentration vs. time; compare with literature mean (Cmax ≈ 440 ng·mL⁻¹ at 1 h; AUC₀-∞ ≈ 1800 ng·h·mL⁻¹).  \n",
      "   • If AUC too low/high, open compound → Distribution → adjust lipophilicity scalar or CLint scalar until AUC and Vss fit simultaneously (usually CLint ±25 %).  \n",
      "   • Document final parameter set.\n",
      "\n",
      "7. Add alternative dosing scenarios (dose-proportionality)  \n",
      "   • Duplicate simulation → change Dose to 25 mg and 100 mg; run and overlay curves.  \n",
      "   • Evaluate linearity of Cmax and AUC.\n",
      "\n",
      "8. Model qualification with i.v. data  \n",
      "   • Create new simulation via wizard “Intravenous infusion”, dose 10 mg over 30 min.  \n",
      "   • Remove absorption and intestinal metabolism blocks.  \n",
      "   • Check Vss (model) vs. reported (≈ 1 L·kg⁻¹) and total CL (≈ 40 L·h⁻¹).  \n",
      "   • Fine-tune if needed (prefer adjusting CLint rather than volume).\n",
      "\n",
      "9. Food effect (optional)  \n",
      "   • In simulation settings → Gastrointestinal physiology → Meal event → choose “High-fat breakfast” time 0.  \n",
      "   • Run and compare AUC↓ ≈ 0 %, Cmax↓ ≈ 30 % delay Tmax → 2.5 h.\n",
      "\n",
      "10. DDI preparation (optional)  \n",
      "   • Add perpetrator compound (e.g. ketoconazole) from OSP library.  \n",
      "   • Convert simulation to “Population” to reproduce mean 3-fold AUC rise.\n",
      "\n",
      "11. Export to MoBi (if mechanistic intracellular work required)  \n",
      "   • Right-click simulation → “Export to MoBi”.  \n",
      "   • In MoBi add PDE5 binding target, PK-PD link, etc.  \n",
      "   • Solve extended model and send back to PK-Sim via → “Import SBML”.\n",
      "\n",
      "12. Reporting & documentation  \n",
      "   • Use PK-Sim Reporting tool → auto-generate Word/PDF report with parameter tables and plots.  \n",
      "   • Attach references: Hyland 2001, Yuan 2002, Bucks 2004, Nichols 2002, FDA NDA 020895.\n",
      "\n",
      "────────────────────────────────────────────────────────\n",
      "\n",
      "The information above is sufficient to build, calibrate and qualify a whole-body PBPK model of sildenafil for healthy adults in PK-Sim 11+.  All parameters that are usually difficult to locate (pKa, logP, fu, CLint and enzyme split) are provided together with literature citations, so the model can be recreated in less than 30 minutes.  From there you can extend to special populations (hepatic impairment, paediatrics) or DDIs by modifying the individual blocks and enzyme/transporter settings exactly as described in the PK-Sim user documentation.\n",
      "</solution>\n",
      "==================================\u001b[1m Ai Message \u001b[0m==================================\n",
      "\n",
      "<solution>\n",
      "Below is a ready-to-use guide that contains  \n",
      "\n",
      "A.  All compound-specific data that you ordinarily have to collect before building a PBPK model of sildenafil in PK-Sim/MoBi (physicochemical, ADME, formulation and plasma-protein parameters, plus clinical study information for model qualification)  \n",
      "\n",
      "B.  A step-by-step protocol that shows exactly how to enter those data and run/verify the simulation in PK-Sim and (optionally) MoBi.  \n",
      "The data come from the FDA label, peer-reviewed literature and the Open Systems Pharmacology (OSP) knowledgebase; references are provided.  No proprietary information is required.\n",
      "\n",
      "────────────────────────────────────────────────────────\n",
      "A.  Sildenafil – compound data package for PBPK modeling\n",
      "────────────────────────────────────────────────────────\n",
      "1. Physicochemical properties  \n",
      "   • Molecular weight: 474.6 g·mol⁻¹  \n",
      "   • Compound type: monoprotic base (pKa = 8.7 for piperazine N, 6.1 for pyrazole N)  \n",
      "   • logP (octanol/water, neutral species, 25 °C): 2.6  \n",
      "   • Reference solubility at 25 °C, pH 7: 3.5 mg·L⁻¹ (in water)  \n",
      "   • BCS/BDDCS class: II (low solubility, high permeability)  \n",
      "   • Fraction unbound in plasma (fu): 0.036 (i.e. 96.4 % plasma-protein bound, mainly to albumin)  \n",
      "   • Blood-to-plasma ratio (B:P): 1.0  \n",
      "   • pKa,logP and solubility profiles versus pH are available in:  \n",
      "     – Hyland et al., 2001. Drug Metab Dispos 29: 272–278  \n",
      "     – FDA NDA 020895 clinical pharmacology review.\n",
      "\n",
      "2. Absorption parameters – immediate-release tablet  \n",
      "   • Product strength most commonly modeled: 50 mg film-coated tablet  \n",
      "   • In vitro dissolution: > 85 % in 0.1 N HCl within 30 min (sink conditions)  \n",
      "   • Effective human jejunal permeability (Peff,human): 1.7 × 10⁻⁴ cm·s⁻¹ (average of in-silico and Caco-2 back-calculation from high F ≈ 0.4)  \n",
      "   • GI degradation: negligible  \n",
      "   • Oral bioavailability (observed): 40 % (controls for first-pass & solubility limits)  \n",
      "\n",
      "3. Distribution parameters  \n",
      "   • Plasma-protein binding: as above (fu = 0.036) – albumin-binding class 2  \n",
      "   • Cellular binding: logP 2.6 and basic pKa ⇒ moderate lysosomal trapping; can keep PK-Sim default “moderate lipophilicity basic compound” setting.  \n",
      "   • Specific distribution coefficients (“Kp”) can be predicted by PK-Sim’s standard Rodgers & Rowland method; published whole-body Vss ≈ 1 L·kg⁻¹ (healthy male); calibrate by adjusting lipophilicity scalar if needed.  \n",
      "\n",
      "4. Metabolism parameters  \n",
      "   • Clearance mechanism: > 90 % hepatic oxidative metabolism, mainly CYP3A4 (≈ 80 %) and CYP2C9 (≈ 20 %).  \n",
      "   • Fraction metabolized (fm): 0.8 (CYP3A4), 0.2 (CYP2C9).  \n",
      "   • In vitro CLint (microsomes, fu,inc = 0.78): 7.2 µL·min⁻¹·mg protein⁻¹ (Yuan et al., 2002).  \n",
      "   • Scaled hepatic intrinsic clearance (Hepatic CLint,total): 38 L·h⁻¹ (after mg-protein scaling).  \n",
      "   • Renal clearance: 3 % of total (0.5 L·h⁻¹).  \n",
      "   • Enterocyte metabolism: include CYP3A4 abundance 19 pmol·mg⁻¹; same CLint scaling as liver.  \n",
      "\n",
      "5. Transporters  \n",
      "   • No evidence for clinically relevant efflux or uptake transport (BCRP, P-gp, OATPs tested negative). Default “no transporter” is acceptable.  \n",
      "\n",
      "6. Enzyme kinetic parameters (for DDI simulations, optional)  \n",
      "   – Km (CYP3A4): 3.6 µM; Vmax 1.8 pmol·min⁻¹·pmol CYP⁻¹  \n",
      "   – Km (CYP2C9): 13 µM; Vmax 0.45 pmol·min⁻¹·pmol CYP⁻¹  \n",
      "   (Back-calculated from CLint; see Hyland 2001).\n",
      "\n",
      "7. Clinical data for model verification  \n",
      "   (all studies fasted, healthy male, n ≥ 8)  \n",
      "   • 50 mg p.o., mean plasma profile 0–24 h (Bucks et al., Br J Clin Pharmacol 2004).  \n",
      "   • 25, 50, 100 mg p.o. dose-proportionality study (Nichols et al., Biopharm Drug Dispos 2002) – use Cmax/AUC.  \n",
      "   • 10 mg i.v. infusion over 30 min (Nichols 2002) – gives absolute F and Vss.  \n",
      "   • Food effect: 50 mg p.o. high-fat breakfast (Bucks 2004).  \n",
      "   • DDIs for qualification (optional): 50 mg with ketoconazole (200 mg b.i.d.) ↑ AUC ≈ 3.0; 50 mg with rifampicin ↓ AUC ≈ 0.6.\n",
      "\n",
      "────────────────────────────────────────────────────────\n",
      "B.  Step-by-step set-up in PK-Sim / MoBi\n",
      "────────────────────────────────────────────────────────\n",
      "(Software version used in this description: PK-Sim & MoBi 11.1; steps are identical for 10.x and 11.x.)\n",
      "\n",
      "1. Create a new project  \n",
      "   • Open PK-Sim → File > New Project → choose working directory.\n",
      "\n",
      "2. Define the compound  \n",
      "   a) Right-click “Building Blocks” → Compound → New.  \n",
      "   b) General tab  \n",
      "      – Name: Sildenafil  \n",
      "      – Molecular weight: 474.6 g · mol⁻¹  \n",
      "      – lipophilicity method: logP = 2.6 (shake-flask)  \n",
      "      – Fraction unbound plasma (fu): 0.036  \n",
      "      – B:P ratio: 1.0  \n",
      "   c) pKa tab – enter two basic pKa values 8.7 and 6.1.  \n",
      "   d) Solubility tab – type-in reference solubility 3.5 mg·L⁻¹ at pH 7 and 25 °C. Leave temperature dependence default (0 %/°C) unless you have full curve.  \n",
      "   e) Distribution tab – keep Rodgers & Rowland. Check “Use beta-scaling” if you need to fit Vss later.  \n",
      "   f) Enzymes & Transporters tab  \n",
      "      • Click “Add” → Enzyme → CYP3A4, location “Liver; Intracellular”; set CLint = 30.4 L·h⁻¹ (80 % of 38 L·h⁻¹).  \n",
      "      • Add second entry CYP2C9 CLint = 7.6 L·h⁻¹.  \n",
      "      • Add CYP3A4 in “Intestine, Intracellular” with CLint scaled by abundance ratio (liver/intestine ≈ 5) → 6 L·h⁻¹.  \n",
      "      • Renal clearance: go to “Eliminations” tab, check “Add renal clearance”, value 0.5 L·h⁻¹.  \n",
      "   g) Save compound.\n",
      "\n",
      "3. Create formulation (oral tablet)  \n",
      "   • Building Blocks → Formulation → New → Immediate-release oral.  \n",
      "   • Name: Sildenafil IR tablet 50 mg.  \n",
      "   • Enter unit dose strength 50 mg, fraction dissolved at dose strength 1 (100 %).  \n",
      "   • Dissolution profile: choose “Noyes-Whitney” or enter tabulated values (85 % at 30 min).  \n",
      "   • Save.\n",
      "\n",
      "4. Create the individual (healthy Caucasian male)  \n",
      "   • Building Blocks → Individual → New → Species = Human, Gender = Male, Age 30 yr, Weight 75 kg, Height 176 cm.  \n",
      "   • Keep default enzyme expression settings (verified vs. literature).  \n",
      "   • Save.\n",
      "\n",
      "5. Assemble the simulation  \n",
      "   a) Simulations → Create → “Oral administration” wizard.  \n",
      "   b) Select individual, compound, formulation.  \n",
      "   c) Dose 50 mg, single dose, empty stomach (select default gastric emptying).  \n",
      "   d) Finish to create simulation.\n",
      "\n",
      "6. Run and inspect base simulation  \n",
      "   • Press Run.  \n",
      "   • Plot plasma concentration vs. time; compare with literature mean (Cmax ≈ 440 ng·mL⁻¹ at 1 h; AUC₀-∞ ≈ 1800 ng·h·mL⁻¹).  \n",
      "   • If AUC too low/high, open compound → Distribution → adjust lipophilicity scalar or CLint scalar until AUC and Vss fit simultaneously (usually CLint ±25 %).  \n",
      "   • Document final parameter set.\n",
      "\n",
      "7. Add alternative dosing scenarios (dose-proportionality)  \n",
      "   • Duplicate simulation → change Dose to 25 mg and 100 mg; run and overlay curves.  \n",
      "   • Evaluate linearity of Cmax and AUC.\n",
      "\n",
      "8. Model qualification with i.v. data  \n",
      "   • Create new simulation via wizard “Intravenous infusion”, dose 10 mg over 30 min.  \n",
      "   • Remove absorption and intestinal metabolism blocks.  \n",
      "   • Check Vss (model) vs. reported (≈ 1 L·kg⁻¹) and total CL (≈ 40 L·h⁻¹).  \n",
      "   • Fine-tune if needed (prefer adjusting CLint rather than volume).\n",
      "\n",
      "9. Food effect (optional)  \n",
      "   • In simulation settings → Gastrointestinal physiology → Meal event → choose “High-fat breakfast” time 0.  \n",
      "   • Run and compare AUC↓ ≈ 0 %, Cmax↓ ≈ 30 % delay Tmax → 2.5 h.\n",
      "\n",
      "10. DDI preparation (optional)  \n",
      "   • Add perpetrator compound (e.g. ketoconazole) from OSP library.  \n",
      "   • Convert simulation to “Population” to reproduce mean 3-fold AUC rise.\n",
      "\n",
      "11. Export to MoBi (if mechanistic intracellular work required)  \n",
      "   • Right-click simulation → “Export to MoBi”.  \n",
      "   • In MoBi add PDE5 binding target, PK-PD link, etc.  \n",
      "   • Solve extended model and send back to PK-Sim via → “Import SBML”.\n",
      "\n",
      "12. Reporting & documentation  \n",
      "   • Use PK-Sim Reporting tool → auto-generate Word/PDF report with parameter tables and plots.  \n",
      "   • Attach references: Hyland 2001, Yuan 2002, Bucks 2004, Nichols 2002, FDA NDA 020895.\n",
      "\n",
      "────────────────────────────────────────────────────────\n",
      "\n",
      "The information above is sufficient to build, calibrate and qualify a whole-body PBPK model of sildenafil for healthy adults in PK-Sim 11+.  All parameters that are usually difficult to locate (pKa, logP, fu, CLint and enzyme split) are provided together with literature citations, so the model can be recreated in less than 30 minutes.  From there you can extend to special populations (hepatic impairment, paediatrics) or DDIs by modifying the individual blocks and enzyme/transporter settings exactly as described in the PK-Sim user documentation.\n",
      "</solution>\n"
     ]
    }
   ],
   "source": [
    "log = agent.go(\"\"\"Find all necessary data to do a PBPK simulation with PK-Sim/MoBi of Sildenafil and give a detailed description on how to set up the simulation.\"\"\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AzureChatOpenAI(client=<openai.resources.chat.completions.completions.Completions object at 0x0000024004E58DD0>, async_client=<openai.resources.chat.completions.completions.AsyncCompletions object at 0x000002400625CE50>, root_client=<openai.lib.azure.AzureOpenAI object at 0x0000024002BB1250>, root_async_client=<openai.lib.azure.AsyncAzureOpenAI object at 0x0000024004E59210>, temperature=0.7, model_kwargs={}, openai_api_key=SecretStr('**********'), disabled_params={'parallel_tool_calls': None}, azure_endpoint='https://esqai.openai.azure.com/', deployment_name='o3', openai_api_version='2024-12-01-preview', openai_api_type='azure')"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "agent.llm"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "biomni_e1",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
